Enliven Therapeutics Inc · Q2 2020 earnings

Briefing

Reported financial results for the second quarter ended June 30, 2020 and reviewed recent business highlights.

Imara Inc. reported financial results for the second quarter ended June 30, 2020. The company's cash, cash equivalents and investments were $106.3 million. Research and development expenses were $7.9 million, and general and administrative expenses were $2.4 million. Net loss attributable to common stockholders was $10.2 million, or $0.59 per share.

• Initiated Phase 2b clinical trials of IMR-687 in sickle cell disease and beta-thalassemia; First patient dosed in Ardent Phase 2b sickle cell clinical trial
• Reported Phase 2a interim safety and efficacy data at the European Hematology Association Annual Congress and promising clinical outcomes in an Open Label Extension Study that tests IMR-687 for longer duration
• IMR-687 granted Orphan Drug, Fast Track and Rare Pediatric designations by the FDA for beta-thalassemia
• Expanded pipeline by conducting preclinical research to evaluate the potential of IMR-687 in heart failure with preserved ejection fraction (HFpEF)

Headline financials

Revenue & EPS history

The Company currently expects that its full-year 2020 research and development expenses will range between $35 million and $40 million and that its full-year 2020 general and administrative expenses will range between $8 million and $10 million. The Company expects that its cash, cash equivalents and investments as of June 30, 2020 will be sufficient to enable it to fund its planned operations into mid-2022.